![7E11C5 [7E11-C5]](http://m.family998.com/static/images/cells-no_picture.jpg)
-
平臺(tái)編號(hào)：bio-68587
-
國際編號(hào)：HB-10494?
-
細(xì)胞信息： 7E11C5 [7E11-C5]
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
7E11C5 [7E11-C5]
生長狀態(tài)：懸浮生長
運(yùn)輸方式：凍存運(yùn)輸
是否是腫瘤細(xì)胞：0
物種來源：小鼠
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1
數(shù)量：大量
ATCC Number：HB-10494?
規(guī)格：48T Designations: 7E11C5 [7E11-C5]
Depositors: ?Cytogen Corporation
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human prostate cancer antigen
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with live LNCaP cells and purified plasma membranes from LNCaP cells.
Spleen cells were fused with P3X63Ag8.653 myeloma cells.
The antibody reacts selectively with cells from both normal and neoplastic prostatic epithelium.
By immunofluorescence staining, the reaction was much stronger with neoplastic than normal epithelium.
The antigen recognized by 7E11C5 appears to be present in sera from patients with prostate cancer.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 90%; DMSO, 10%
Storage temperature: liquid nitrogen vapor temperature
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 21308: Horoszewicz JS. Hybridoma and monoclonal antibody 9H10-A4 specific to an antigen of LNCaP cells. US Patent 5,578,484 dated Nov 26 1996
22007: Horoszewicz JS. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. US Patent 5,162,504 dated Nov 10 1992
運(yùn)輸方式：凍存運(yùn)輸
是否是腫瘤細(xì)胞：0
物種來源：小鼠
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1
數(shù)量：大量
ATCC Number：HB-10494?
規(guī)格：48T Designations: 7E11C5 [7E11-C5]
Depositors: ?Cytogen Corporation
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human prostate cancer antigen
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with live LNCaP cells and purified plasma membranes from LNCaP cells.
Spleen cells were fused with P3X63Ag8.653 myeloma cells.
The antibody reacts selectively with cells from both normal and neoplastic prostatic epithelium.
By immunofluorescence staining, the reaction was much stronger with neoplastic than normal epithelium.
The antigen recognized by 7E11C5 appears to be present in sera from patients with prostate cancer.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 90%; DMSO, 10%
Storage temperature: liquid nitrogen vapor temperature
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 21308: Horoszewicz JS. Hybridoma and monoclonal antibody 9H10-A4 specific to an antigen of LNCaP cells. US Patent 5,578,484 dated Nov 26 1996
22007: Horoszewicz JS. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. US Patent 5,162,504 dated Nov 10 1992
